MarketPulse

GLSI-100

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences' GLSI-100 Data Gets ASCO Platform; 70-80% Recurrence Reduction Shown

Greenwich LifeSciences' GLSI-100 breast cancer immunotherapy receives ASCO 2026 abstract acceptance, showing 70-80% recurrence reduction in Phase III trial.
GLSIGLSI-100FLAMINGO-01
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Posts Promising FLAMINGO-01 Data on Breast Cancer Immunotherapy

Greenwich LifeSciences reports significant immune response gains in Phase III FLAMINGO-01 trial for GLSI-100 breast cancer recurrence prevention, showing 70-80% recurrence reduction.
GLSIbreast cancerGLSI-100
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Doubles Market for GP2 Cancer Therapy With Expanded Patent Claims

Greenwich LifeSciences expands GLSI-100 breast cancer therapy addressable market by 100% through new patent claims extending to 2045, adding 88,000 potential patients annually.
GLSIGLSI-100FLAMINGO-01
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Expands FLAMINGO-01 Trial With City of Hope, Advances Breast Cancer Immunotherapy

Greenwich LifeSciences expands FLAMINGO-01 trial with City of Hope, growing sites to 190-200. Preliminary data shows 70-80% recurrence reduction in breast cancer immunotherapy study.
GLSIbreast cancerGLSI-100
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Shows Promise for Breast Cancer Prevention at AACR 2026

$GLSI's GLSI-100 immunotherapy demonstrates 70-80% recurrence reduction in Phase III trial data accepted for AACR presentation.
GLSIbreast cancerGLSI-100
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Scales GP2 Production as Phase III Trial Hits Manufacturing Milestone

Greenwich LifeSciences deploys commercially manufactured GP2 across all 40 FLAMINGO-01 trial sites following FDA approval, scaling production capacity significantly.
GLSIFDA approvalcommercial manufacturing
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Accelerates FLAMINGO-01 Trial With 33% Patient Screening Surge

Greenwich LifeSciences boosts FLAMINGO-01 screening by 33% to 800 patients yearly, with non-HLA-A*02 arm fully enrolled and showing 80% recurrence reduction.
GLSIbreast cancerGLSI-100
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Presents FLAMINGO-01 Trial Data at AACR 2026 Conference

Greenwich LifeSciences presents FLAMINGO-01 Phase III trial data at AACR 2026, showing 80% recurrence reduction. Non-HLA-A*02 arm fully enrolled with 250 patients.
GLSIbreast cancerGLSI-100